FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1521958559> ?p ?o ?g. }

• W1521958559 endingPage "195" @default.
• W1521958559 startingPage "189" @default.
• W1521958559 abstract "Summary Targeting aberrant DNA hypermethylation in chronic lymphocytic leukaemia (CLL) and non‐Hodgkin lymphoma (NHL) with decitabine may reverse epigenetic silencing in B‐cell malignancies. Twenty patients were enrolled in two phase I trials to determine the minimum effective pharmacological dose of decitabine in patients with relapsed/refractory CLL ( n = 16) and NHL ( n = 4). Patients received 1–3 cycles of decitabine. Dose‐limiting toxicity (DLT) was observed in 2 of 4 CLL and 2 of 2 NHL patients receiving decitabine at 15 mg/m 2 per d days 1–10, consisting of grade 3–4 thrombocytopenia and hyperbilirubinaemia. Six patients with CLL received decitabine at 10 mg/m 2 per d days 1–10 without DLT; however, re‐expression of methylated genes or changes in global DNA methylation were not observed. Therefore, a 5‐day decitabine schedule was examined. With 15 mg/m 2 per d decitabine days 1–5, DLT occurred in 2 of 6 CLL and 2 of 2 NHL patients, consisting of grade 3–4 neutropenia, thrombocytopenia, and febrile neutropenia. Eight patients had stable disease. In 17 patients, there were no significant changes in genome‐wide methylation or in target gene re‐expression. In conclusion, dose‐limiting myelosuppression and infectious complications prevented dose escalation of decitabine to levels associated with changes in global methylation or gene re‐expression in CLL and NHL." @default.
• W1521958559 created "2016-06-24" @default.
• W1521958559 creator A5000921376 @default.
• W1521958559 creator A5007847102 @default.
• W1521958559 creator A5012262072 @default.
• W1521958559 creator A5012846289 @default.
• W1521958559 creator A5013825368 @default.
• W1521958559 creator A5019749214 @default.
• W1521958559 creator A5020136143 @default.
• W1521958559 creator A5034609249 @default.
• W1521958559 creator A5039283256 @default.
• W1521958559 creator A5051480539 @default.
• W1521958559 creator A5051619378 @default.
• W1521958559 creator A5055443268 @default.
• W1521958559 creator A5056111187 @default.
• W1521958559 creator A5056946123 @default.
• W1521958559 creator A5060959458 @default.
• W1521958559 creator A5084771066 @default.
• W1521958559 date "2010-07-01" @default.
• W1521958559 modified "2023-10-17" @default.
• W1521958559 title "Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation" @default.
• W1521958559 cites W1912693401 @default.
• W1521958559 cites W1963919702 @default.
• W1521958559 cites W1964136936 @default.
• W1521958559 cites W1978768129 @default.
• W1521958559 cites W2015859315 @default.
• W1521958559 cites W2022240113 @default.
• W1521958559 cites W2030352564 @default.
• W1521958559 cites W2038067709 @default.
• W1521958559 cites W2058444707 @default.
• W1521958559 cites W2068296418 @default.
• W1521958559 cites W2097459133 @default.
• W1521958559 cites W2103163028 @default.
• W1521958559 cites W2109895173 @default.
• W1521958559 cites W2117291755 @default.
• W1521958559 cites W2146777419 @default.
• W1521958559 cites W2147177643 @default.
• W1521958559 cites W2162037712 @default.
• W1521958559 cites W2163710445 @default.
• W1521958559 cites W3147148312 @default.
• W1521958559 cites W4229952372 @default.
• W1521958559 cites W4384116820 @default.
• W1521958559 cites W60865865 @default.
• W1521958559 doi "https://doi.org/10.1111/j.1365-2141.2010.08213.x" @default.
• W1521958559 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2917115" @default.
• W1521958559 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20456354" @default.
• W1521958559 hasPublicationYear "2010" @default.
• W1521958559 type Work @default.
• W1521958559 sameAs 1521958559 @default.
• W1521958559 citedByCount "23" @default.
• W1521958559 countsByYear W15219585592012 @default.
• W1521958559 countsByYear W15219585592013 @default.
• W1521958559 countsByYear W15219585592015 @default.
• W1521958559 countsByYear W15219585592016 @default.
• W1521958559 countsByYear W15219585592019 @default.
• W1521958559 countsByYear W15219585592020 @default.
• W1521958559 countsByYear W15219585592021 @default.
• W1521958559 countsByYear W15219585592022 @default.
• W1521958559 countsByYear W15219585592023 @default.
• W1521958559 crossrefType "journal-article" @default.
• W1521958559 hasAuthorship W1521958559A5000921376 @default.
• W1521958559 hasAuthorship W1521958559A5007847102 @default.
• W1521958559 hasAuthorship W1521958559A5012262072 @default.
• W1521958559 hasAuthorship W1521958559A5012846289 @default.
• W1521958559 hasAuthorship W1521958559A5013825368 @default.
• W1521958559 hasAuthorship W1521958559A5019749214 @default.
• W1521958559 hasAuthorship W1521958559A5020136143 @default.
• W1521958559 hasAuthorship W1521958559A5034609249 @default.
• W1521958559 hasAuthorship W1521958559A5039283256 @default.
• W1521958559 hasAuthorship W1521958559A5051480539 @default.
• W1521958559 hasAuthorship W1521958559A5051619378 @default.
• W1521958559 hasAuthorship W1521958559A5055443268 @default.
• W1521958559 hasAuthorship W1521958559A5056111187 @default.
• W1521958559 hasAuthorship W1521958559A5056946123 @default.
• W1521958559 hasAuthorship W1521958559A5060959458 @default.
• W1521958559 hasAuthorship W1521958559A5084771066 @default.
• W1521958559 hasBestOaLocation W15219585592 @default.
• W1521958559 hasConcept C104317684 @default.
• W1521958559 hasConcept C126322002 @default.
• W1521958559 hasConcept C143998085 @default.
• W1521958559 hasConcept C150194340 @default.
• W1521958559 hasConcept C190727270 @default.
• W1521958559 hasConcept C203014093 @default.
• W1521958559 hasConcept C2776012956 @default.
• W1521958559 hasConcept C2776694085 @default.
• W1521958559 hasConcept C2777063308 @default.
• W1521958559 hasConcept C2778850193 @default.
• W1521958559 hasConcept C2779338263 @default.
• W1521958559 hasConcept C2780235182 @default.
• W1521958559 hasConcept C54355233 @default.
• W1521958559 hasConcept C71924100 @default.
• W1521958559 hasConcept C86803240 @default.
• W1521958559 hasConcept C90924648 @default.
• W1521958559 hasConceptScore W1521958559C104317684 @default.
• W1521958559 hasConceptScore W1521958559C126322002 @default.
• W1521958559 hasConceptScore W1521958559C143998085 @default.
• W1521958559 hasConceptScore W1521958559C150194340 @default.
• W1521958559 hasConceptScore W1521958559C190727270 @default.

• next